Developing a deep learning-based imaging diagnostic framework, PVDNet, for differentiating pulmonary artery sarcoma and pulmonary thromboembolism: a multi-center observational study
Min Liu(China-Japan Friendship Hospital), Fajiu Li(Wuhan Sixth Hospital), Yinsu Zhu(Jiangsu Cancer Hospital), Qiang Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Minjie Lu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoyan Lei(Peking University), Cong Shen(Suzhou Municipal Hospital), Rongguo Zhang(Capital Normal University), Hongjie Hu(University of California San Diego), Ziyang Zhu(University of Electronic Science and Technology of China), Yu Deng(Capital Medical University), Jianping Wang(Sun Yat-sen University), Xin Chen(Montana State University), Lihua Wang(Jiangxi University of Traditional Chinese Medicine), Hui Liu(Zhengzhou University), Heng Ma(Air Force Medical University), Xiaoyan Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaopeng Liu(China-Japan Friendship Hospital), Anqi Liu(Shanxi Dayi Hospital), Xiaojuan Guo(Capital Medical University), Yifei Ni(Chinese Academy of Medical Sciences & Peking Union Medical College), Zixian Chen(First Hospital of Lanzhou University), Han Sung Kang(Ulsan College), Liqing Peng(Sichuan University), Hongyi Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Wanmu Xie(China-Japan Friendship Hospital), Yanan Zhen(China-Japan Friendship Hospital), Xincao Tao(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhenguo Zhai(Chinese Academy of Medical Sciences & Peking Union Medical College), Hong Yu(University of Miami), Yinzhu Chen(China Agricultural University)
Cited by 1
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study
|The Lancet|2021|1.1k
The path to healthy ageing in China: a Peking University–Lancet Commission
|The Lancet|2022|955